Can choline-C11 PET/CT scan data predict survival in men with recurrent prostate cancer?

We know that [11C]choline PET/CT scanning can be used to identify sites of recurrence of prostate cancer in men with a rising PSA after first-line therapy. What we do not yet know with clarity is whether such PET/CT scans have any real prognostic value. … READ MORE …

The FDA’s “take” on pre-chemo approval of abiraterone in mCRPC

A new article in Clinical Cancer Research offers us insights into the US Food and Drug Administration’s thinking about the approval of abiraterone acetate for the treatment of chemotherapy-naive patients with metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …

Pre-diagnostic aspirin use and prostate cancer-related mortality

An article just published in Renal & Urology News states that “Men who take aspirin doses above 75 mg have a significantly reduced risk of death from prostate cancer … compared with men who do not take aspirin.” … READ MORE …

No decrease in mortality rate of newly diagnosed men with metastatic prostate cancer

A newly published paper in the journal Cancer has indicated that, here in the USA, although overall prostate cancer mortality has declined by ~ 40 percent during the past 25 years, there has been no significant decrease in the mortality rate among men who have evident metastatic prostate cancer at time of diagnosis. … READ MORE …

Long-term outcomes of higher- vs. lower-dose radiation therapy

There is still no absolute clarity to the degree of benefit associated with higher-dose as opposed to older, lower-dose external beam radiation therapy for men with localized prostate cancer. … READ MORE …

Does statin therapy really extend survival of men diagnosed with prostate cancer?

An analysis of another large cohort of prostate cancer patients (this time from the United Kingdom) has again suggested that there is a reduction in the risk of prostate cancer-specific mortality for patients who are treated with statins after their initial diagnosis with prostate cancer. … READ MORE …

Ability to project long-term response to treatment with abiraterone acetate + prednisone

A report published yesterday on the OncLive web site discusses a presentation by Dr. Howard Scher at the 2013 European Cancer Congress in Amsterdam. Dr. Scher reported that a panel of biomarkers could identify men with metastatic, castration-resistant prostate cancer (mCRPC) who were responding well or less well to treatment with abiraterone + prednisone. … READ MORE …

New study links quality of life data to median overall survival in prostate cancer

An “exploratory study”, published recently in BMC Urology, offers us evidence that men with prostate cancer who have less baseline fatigue and those whose dyspnea and cognitive functioning improves within 3 months of treatment have a significantly increased probability of survival. … READ MORE …

Can metformin extend survival of prostate cancer patients with (or without) diabetes?

A retrospective analysis of data from  > 3,800 Canadian men has suggested that diabetic men who also had prostate cancer and were being treated with a commonly used, generic drug called metformin have a reduced risk for death from prostate cancer. … READ MORE …

Baseline data from the control arm of the STAMPEDE trial

One of the more interesting sets of data on metastatic prostate cancer to be presented at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago this year will be some of the very earliest data from the STAMPEDE trial, which we have discussed in some detail in an earlier post. … READ MORE …

Prostate cancer-specific mortality and diagnosis with BRCA1/2-positive disease

A new study just published on line in the Journal of Clinical Oncology had confirmed that “BRCA1/2 mutations confer a more aggressive [prostate cancer] phenotype with a higher probability of nodal involvement and distant metastasis.” This is not a surprising finding, but it does have real implications for men with a family history of BRCA1/2 mutations. … READ MORE …

The developing Cancer Survival Query System (CSQS) and its application to prostate cancer

Just over a month ago we mentioned the CSQS in commenting on a Swedish paper (by Eloranta et al.) that dealt with prediction of the “crude” or “real world” probability of death from prostate cancer (as opposed to potential, competing causes of death). … READ MORE …

Overall survival among participants in the Prostate Cancer Prevention Trial

The Prostate Cancer Prevention Trial (PCPT) showed that treatment with finasteride (a 5α-reductase inhibitor) could lower the number of prostate cancers diagnosed in the U.S. each year by about 25 percent. … READ MORE …

Median OS of men with CRPC may have doubled since 2003

A new article in European Urology suggests that the mean life expectancy for men participating in recent clinical trials and expanded access programs for new drugs for the treatment of chemotherapy-naive, castration-resistant prostate cancer (CRPC) — including metastatic and non-metastatic patients — is now just over 30 months. … READ MORE …

The practical utility of prostate cancer survival and mortality data for clinicians and patients

Imagine that you are 65 years of age and have just been diagnosed with intermediate-risk prostate cancer (clinical stage T1c; PSA 3.7 ng/ml; Gleason 3 + 4 = 7; with 3/12 biopsy cores positive for cancer, all in the left lobe). You understand quickly that this places you at some risk for progressive disease, and perhaps even for prostate cancer-specific mortality. … READ MORE …

Follow

Get every new post delivered to your Inbox.

Join 1,074 other followers